{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"Treatment-Emergent Adverse Events (TEAE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0"}]}],"title":"Serious Treatment-Emergent Adverse Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"}],"units":"Participants"}],"groups":[{"description":"Epacadostat 100 mg tablet orally BID in combination with pembrolizumab 200 mg intravenously every 3 weeks (Q3W).","id":"OG000","title":"Phase 2: Epacadostat 100 mg BID"}],"paramType":"NUMBER","populationDescription":"The safety evaluable population included all participants enrolled in the study who received at least 1 dose of study drug (epacadostat or pembrolizumab). Treatment groups for this population were determined according to the actual treatment the participant receives on Day 1. All safety analyses were conducted using the safety evaluable population.","reportingStatus":"POSTED","timeFrame":"Up to 54 months","title":"Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}